| Dr Bee L Wee, PHARMD | |
|
4220 Lexington Ave S, Eagan, MN 55123-1975 | |
| (651) 686-1090 | |
| Not Available |
| Full Name | Dr Bee L Wee |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4220 Lexington Ave S, Eagan, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033495064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 116101 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bee L Wee, PHARMD 513 Spruce St, Eagan, MN 55123-4910 Ph: (651) 405-8273 | Dr Bee L Wee, PHARMD 4220 Lexington Ave S, Eagan, MN 55123-1975 Ph: (651) 686-1090 |
News Archive
The National Institutes of Health announced today it will award $17 million this year for 24 research projects designed to improve scientists' understanding of a newly discovered type of cell-to-cell communication based on extracellular (outside the cell) RNA, also called exRNA.
In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody® Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE).
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.
› Verified 7 days ago
Mr. Mohamed Ahmed Aw-dahir, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2010 Cliff Rd, Eagan, MN 55122 Phone: 651-686-6940 Fax: 651-686-1072 | |
Xia Xiong, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1940 Cliff Lake Rd, Eagan, MN 55122 Phone: 651-454-5150 | |
Dr. Sheri Ann Beaupre, PHARM D., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1020 Diffley Rd, Eagan, MN 55123 Phone: 651-452-5500 Fax: 651-452-3102 | |
Leslie Anne Condon, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4733 Covington Ct, Eagan, MN 55122 Phone: 651-905-9268 | |
Hima B Pallempati, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1274 Town Centre Dr, Eagan, MN 55123 Phone: 651-452-5321 | |
Dr. Alan H Heaton, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1750 Yankee Doodle Rd, Eagan, MN 55121 Phone: 651-662-8758 Fax: 651-662-8758 |